… 22Rv1), Prostate Cancer-3 (PC3) with its docetaxel-resistant derivative PC3-Docetaxel Resistant … micromolar cytotoxicity across diverse prostate-cancer phenotypes, bypasses major … the anticancer arsenal against prostate tumors that evade current standards. …

… treatment outcomes for advanced prostate cancer. OncLive: What … in metastatic castration-sensitive prostate cancer (mCSPC)? Treatment … in metastatic hormone-sensitive prostate cancer (mHSPC)? Patient selection … the addition of docetaxel to the backbone …

… cancer, particularly breast and prostate cancers. By 2033, the … of hormone-refractory prostate cancer and metastatic breast cancer … generic availability post-Taxotere patent expiry. While … 3. Docetaxel Market: Competitive Analysis 4. Docetaxel Market: Macro …

… evolving landscape of prostate cancer treatment, highlighting … metastatic castrate-sensitive prostate cancer. The clinicians discussed … starting treatments like docetaxel. Discussing patient … potential future of prostate cancer management, contemplating …

… patients with metastatic hormone-sensitive prostate cancer (mHSPC) did not significantly improve … radiotherapy, and with or without docetaxel or an androgen receptor pathway … , and 82% received ADT plus docetaxel. No Overall Survival Benefit Observed …

… with metastatic hormone-sensitive prostate cancer (mHSPC). The approval … use with ADT and docetaxel in mHSPC, and with … non-metastatic castration-resistant prostate cancer (nmCRPC) in patients … 115,000 deaths. Prostate cancer diagnoses are projected to …

… for use with ADT and docetaxel in mHSPC, and with … ADT or plus ADT and docetaxel) demonstrated a side effect … , in combination with chemotherapy docetaxel and/or an … eventually progress to castration-resistant prostate cancer, a condition with limited …

… one third of prostate cancers respond poorly to treatment … of care for advanced prostate cancer. Many patients will … response program.” Docetaxel is approved in prostate cancer treatment but is … good candidates for earlier docetaxel treatment.” The researchers …

… care for advanced prostate cancer. While many patients … outcomes from several prostate cancer clinical trial datasets. … program. Docetaxel is approved for prostate cancer but typically … expression program between prostate cancers that do exceptionally …

Panelists discuss how the ARASENSE and PEACE-1 phase 3 trials demonstrated the efficacy of triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and novel antiandrogens, while addressing the ongoing underutilization of intensified …